BIOCRYST PHARMACEUTICALS INC (BCRX)       12.52  +0.41 (+3.39%)

12.52  +0.41 (+3.39%)

US09058V1035 - Common Stock - After market: 12.52 0 (0%)

News Image
7 days ago - InvestorPlace

3 Biotech Stocks to Buy Now for Extraordinary Gains

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

News Image
14 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief...

News Image
22 days ago - BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

News Image
a month ago - BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image
a month ago - BioCryst Pharmaceuticals, Inc.

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug...

News Image
a month ago - BioCryst Pharmaceuticals, Inc.

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Study represents first data with BCX9930 in C3G patients...

News Image
a month ago - BioCryst Pharmaceuticals, Inc.

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of...

News Image
a month ago - BioCryst Pharmaceuticals, Inc.

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and...

News Image
2 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones

—Q2 2022 ORLADEYO net revenue of $65.2 million— —FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million— RESEARCH TRIANGLE...

News Image
2 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Resumes Enrollment in BCX9930 Clinical Program

—U.S. Food and Drug Administration lifts partial clinical hold—...

News Image
2 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst to Report Second Quarter 2022 Financial Results on August 4

RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image
2 months ago - Market News Video

First Week of BCRX March 2023 Options Trading

News Image
3 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., July 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image
3 months ago - BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

—Analysis from APeX-S showed 98 percent attack-free days during treatment with ORLADEYO after switching from an injectable therapy—...